NHS Logo
Image from Google Jackets

Drug Eruptions [E-Book]

Contributor(s): Series: Updates in Clinical DermatologyPublisher: Cham : Springer International Publishing : Imprint: Springer, 2022Edition: 1st ed. 2022Description: XX, 337 p. 109 illus., 107 illus. in color. online resourceContent type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9783031093883
Subject(s): Online resources:
Contents:
Section I: General Considerations -- Chapter 1: Pharmacogenetics of Cutaneous Adverse Drug Reactions -- Chapter 2: Mechanisms of Drug Hypersensitivity -- Chapter 3: Histopathology of Cutaneous Adverse Drug Reactions -- Chapter 4: Skin Tests in Evaluating Drug Eruptions -- Chapter 5: In vitro Drug Allergy Testing -- Section II: Reaction Patterns -- Chapter 6: Drug-induced urticaria -- Chapter 7: Exanthematous Drug Eruptions -- Chapter 8: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis -- Chapter 9: Acute Generalized Exanthematous Pustulosis -- Chapter 10: Drug Reaction Eosinophilia and Systemic Symptoms (DRESS) -- Chapter 11: Fixed Drug Eruptions and Generalized Bullous Fixed Drug Eruptions -- Chapter 12: Lichenoid Drug Eruptions -- Chapter 13: Drug-induced Connective Tissue Disorders -- Chapter 14: Drug-induced Vasculitis -- Chapter 15: Drug-induced Autoimmune Bullous Diseases -- Chapter 16: Other Drug-induced Inflammatory Skin Reactions -- Chapter 14: Drug-induced Vasculitis -- Chapter 15: Drug-induced Autoimmune Bullous Diseases -- Chapter 16: Other Drug-induced Inflammatory Skin Reactions -- Chapter 17: Drug-induced Photosensitivity -- Chapter 18: Drug-induced Pruritus Without Primary Rash -- Chapter 19: Drug-induced Nail Changes -- Chapter 20: Drug-induced Hair Changes -- Chapter 21: Drug-induced Pigmentary Disorders -- Section III: Special Drug Categories -- Chapter 22: Immediate and Delayed Reactions to Beta-lactams -- Chapter 23: Hypersensitivity Reactions to Iodinated Radiocontrast Media -- Chapter 24: Cutaneous Adverse Reactions to Biologic Agents -- Chapter 25: Cutaneous Reactions to Oncologic Targeted Therapy -- Chapter 26 :Cutaneous Reactions to Oncologic Immunotherapy. .
Summary: Cutaneous adverse drug reactions are common and range from the benign to those which are life-threatening. The clinical presentation of these dermatoses is varied and many may mimic common skin conditions. Consequently, diagnosis in drug-induced skin disease is challenging and the treatment considerations are complex. This book aims to bridge the divide between dermatology and allergy by providing a comprehensive review on the pathomechanisms and clinical features of cutaneous adverse drug reactions. Broken up into three distinct sections: General Considerations, Reaction Patterns, and Special Drug Categories, these chapters cover the common and rare adverse skin reactions and provide information on recent advances - particularly immunopathology and pharmacogenetics - as well as highlighting new adverse drug signals and novel therapies. Drug Eruptions is a must-have resource for dermatologists, allergists, internal physicians and general practitioners.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Class number URL Status Date due Barcode
Electronic book Hillingdon Hospitals Library Services (Hillingdon Hospitals NHS Foundation) Online Link to resource Available

Section I: General Considerations -- Chapter 1: Pharmacogenetics of Cutaneous Adverse Drug Reactions -- Chapter 2: Mechanisms of Drug Hypersensitivity -- Chapter 3: Histopathology of Cutaneous Adverse Drug Reactions -- Chapter 4: Skin Tests in Evaluating Drug Eruptions -- Chapter 5: In vitro Drug Allergy Testing -- Section II: Reaction Patterns -- Chapter 6: Drug-induced urticaria -- Chapter 7: Exanthematous Drug Eruptions -- Chapter 8: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis -- Chapter 9: Acute Generalized Exanthematous Pustulosis -- Chapter 10: Drug Reaction Eosinophilia and Systemic Symptoms (DRESS) -- Chapter 11: Fixed Drug Eruptions and Generalized Bullous Fixed Drug Eruptions -- Chapter 12: Lichenoid Drug Eruptions -- Chapter 13: Drug-induced Connective Tissue Disorders -- Chapter 14: Drug-induced Vasculitis -- Chapter 15: Drug-induced Autoimmune Bullous Diseases -- Chapter 16: Other Drug-induced Inflammatory Skin Reactions -- Chapter 14: Drug-induced Vasculitis -- Chapter 15: Drug-induced Autoimmune Bullous Diseases -- Chapter 16: Other Drug-induced Inflammatory Skin Reactions -- Chapter 17: Drug-induced Photosensitivity -- Chapter 18: Drug-induced Pruritus Without Primary Rash -- Chapter 19: Drug-induced Nail Changes -- Chapter 20: Drug-induced Hair Changes -- Chapter 21: Drug-induced Pigmentary Disorders -- Section III: Special Drug Categories -- Chapter 22: Immediate and Delayed Reactions to Beta-lactams -- Chapter 23: Hypersensitivity Reactions to Iodinated Radiocontrast Media -- Chapter 24: Cutaneous Adverse Reactions to Biologic Agents -- Chapter 25: Cutaneous Reactions to Oncologic Targeted Therapy -- Chapter 26 :Cutaneous Reactions to Oncologic Immunotherapy. .

Cutaneous adverse drug reactions are common and range from the benign to those which are life-threatening. The clinical presentation of these dermatoses is varied and many may mimic common skin conditions. Consequently, diagnosis in drug-induced skin disease is challenging and the treatment considerations are complex. This book aims to bridge the divide between dermatology and allergy by providing a comprehensive review on the pathomechanisms and clinical features of cutaneous adverse drug reactions. Broken up into three distinct sections: General Considerations, Reaction Patterns, and Special Drug Categories, these chapters cover the common and rare adverse skin reactions and provide information on recent advances - particularly immunopathology and pharmacogenetics - as well as highlighting new adverse drug signals and novel therapies. Drug Eruptions is a must-have resource for dermatologists, allergists, internal physicians and general practitioners.

There are no comments on this title.

to post a comment.
London Health Libraries Consortium Privacy notice and Membership terms and conditions